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Abstract 
Background: Diabetes is a risk factor for atherosclerosis associated with oxidative stress, inflammation and cell 
proliferation. The purpose of this study was to evaluate arterial choline uptake and its relationship to atherosclerotic 
inflammation in diabetic and non‑diabetic hypercholesterolemic mice.
Methods: Low‑density lipoprotein‑receptor deficient mice expressing only apolipoprotein B100, with or without 
type 2 diabetes caused by pancreatic overexpression of insulin‑like growth factor II (IGF‑II/LDLR−/−ApoB100/100 and 
LDLR−/−ApoB100/100) were studied. Distribution kinetics of choline analogue 18F‑fluoromethylcholine (18F‑FMCH) 
was assessed in vivo by positron emission tomography (PET) imaging. Then, aortic uptakes of 18F‑FMCH and glucose 
analogue 18F‑fluorodeoxyglucose (18F‑FDG), were assessed ex vivo by gamma counting and autoradiography of tissue 
sections. The 18F‑FMCH uptake in atherosclerotic plaques was further compared with macrophage infiltration and the 
plasma levels of cytokines and metabolic markers.
Results: The aortas of all hypercholesterolemic mice showed large, macrophage‑rich atherosclerotic plaques. The 
plaque burden and densities of macrophage subtypes were similar in diabetic and non‑diabetic animals. The blood 
clearance of 18F‑FMCH was rapid. Both the absolute 18F‑FMCH uptake in the aorta and the aorta‑to‑blood uptake ratio 
were higher in diabetic than in non‑diabetic mice. In autoradiography, the highest 18F‑FMCH uptake co‑localized 
with macrophage‑rich atherosclerotic plaques. 18F‑FMCH uptake in plaques correlated with levels of total cholesterol, 
insulin, C‑peptide and leptin. In comparison with 18F‑FDG, 18F‑FMCH provided similar or higher plaque‑to‑background 
ratios in diabetic mice.
Conclusions: Type 2 diabetes enhances the uptake of choline that reflects inflammation in atherosclerotic plaques in 
mice. PET tracer 18F‑FMCH is a potential tool to study vascular inflammation associated with diabetes.
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Background
Diabetes is associated with an increased risk of athero-
sclerotic cardiovascular disease (CVD), and it is common 
in patients with known or at risk of CVD [1]. Various fac-
tors, including increased oxidative stress and subsequent 
activation of pro-inflammatory pathways, as well as 
increased cell proliferation in the arterial wall, contribute 
to accelerated atherosclerosis in diabetes [2]. Inflamma-
tion is a key factor in the pathogenesis of atherosclerosis 
and its complications [3–5]. Positron emission tomog-
raphy (PET) with a glucose analogue 2-deoxy-2-[18F]-
fluoro-d-glucose (18F-FDG) is a feasible method for 
non-invasive imaging of atherosclerotic plaque inflam-
mation in large arteries. Vascular uptake of 18F-FDG 
has also been observed in individuals without symp-
toms of CVD, in the presence of type 2 diabetes mellitus 
(T2DM) [6, 7], metabolic syndrome [8] and obesity [9]. 
Accumulation of 18F-FDG in atherosclerotic plaques has 
been attributed to high glucose uptake in macrophages 
[4, 10]. In addition to the number of macrophages, 18F-
FDG uptake may reflect their polarization [11, 12] or 
augmentation of glucose uptake induced by hypoxia [13, 
14]. Furthermore, high blood glucose levels in T2DM can 
diminish 18F-FDG uptake in atherosclerosis [7]. These 
factors may complicate the interpretation of 18F-FDG 
signal from arteries, especially in diabetic individuals, 
and therefore, alternative tracers for the quantification of 
inflammation in atherosclerosis have been investigated 
[15–17].
Choline is taken up into cells by choline transport-
ers, phosphorylated by choline kinase, further metabo-
lized to phosphatidylcholine, and eventually incorporated 
into the cell membrane or used for lipoprotein assembly. 
Radiolabeled derivatives of choline have been utilized to 
detect increased choline uptake in tumor cells [18, 19] 
and in macrophages at the sites of inflammation [20, 21]. 
Previous studies have shown increased accumulation of 
radiolabeled choline derivatives in macrophage-rich ath-
erosclerotic lesions [22, 23] or aortic aneurysms [24]. In 
asymptomatic patients, 11C-choline or 18F-fluoromethyl-
choline (18F-FMCH) uptake has been detected in large ves-
sels, predominantly in non-calcified atherosclerotic lesions 
[25, 26]. We hypothesized that the pro-inflammatory 
phenotype in T2DM is associated with increased choline 
uptake, thus making 18F-FMCH a potential tracer for mon-
itoring the progression of atherosclerosis in diabetes.
For this study, we evaluated the uptake of 18F-FMCH 
and 18F-FDG in inflamed atherosclerotic plaques in non-
diabetic and diabetic hypercholesterolemic mice [27]. We 
studied the kinetics and biodistribution of 18F-FMCH by 
PET/computed tomography (CT) imaging and in ex vivo 
tissue samples. Uptake of 18F-FMCH or 18F-FDG in ath-
erosclerotic aorta was first quantified by gamma counting 
and then compared between plaques and adjacent nor-
mal vessel wall by autoradiography of aortic tissue sec-
tions. Furthermore, 18F-FMCH uptake was compared 
with the extent and phenotype of macrophages in ath-
erosclerotic plaques, the plasma levels of inflammatory 
mediators and metabolic markers.
Methods
Animals and study design
We utilized two hypercholesterolemic mouse models in 
the study. LDLR−/−ApoB100/100 mice are deficient in low-
density lipoprotein (LDL) receptor and express only apoli-
poprotein B100 (strain #003000, The Jackson Laboratory, 
Bar Harbor, ME, USA). IGF-II/LDLR−/−ApoB100/100 mice 
(A. I. Virtanen Institute for Molecular Sciences, Univer-
sity of Eastern Finland, Kuopio, Finland) have a similar 
lipid profile as LDLR−/−ApoB100/100, and additionally 
represent the characteristics of T2DM (insulin resistance 
and impaired glucose tolerance in the presence of mildly 
elevated fasting glucose levels) due to the overexpression 
of insulin-like growth factor II (IGF-II) in pancreatic beta 
cells [27, 28]. The mice were fed, for a period of 4 months, 
with a high-fat diet (TD.88137 adjusted calories diet, 
Harlan Teklad, 42 % of calories from fat, 0.2 % total cho-
lesterol, no sodium cholate, Harlan Laboratories, Madi-
son, WI, USA) to accelerate atherosclerosis development.
Accumulation of 18F-FMCH in atherosclerotic plaques 
was compared in LDLR−/−ApoB100/100 and IGF-II/
LDLR−/−ApoB100/100 mice (n  =  11/group) at the age 
of 6–7  months, after 4  months on high-fat diet. For 
comparison, age- and gender-matched groups of mice 
(n = 11–12/group) were similarly studied using 18F-FDG. 
Healthy C57BL/6N mice fed with normal chow diet (age 
8 months, n = 13) were studied with 18F-FMCH as con-
trols. The characteristics of the study animals are shown 
in Table  1. Data on additional 8–10-month-old IGF-II/
LDLR−/−ApoB100/100 mice fed with a longer high-fat diet 
are shown in the Additional file 1.
All the animal experiments were performed in 
accordance with the relevant European Union Direc-
tive and approved by the National Animal Experi-
ment Board in Finland and the Regional State 
Administrative Agency for Southern Finland 
(Licence numbers ESAVI/1583/04.10.03/2012 and 
ESAVI/2163/04.10.07/2015). The mice were housed in 
standardized conditions with a 12/12  h dark/light cycle 
and they had access to water and food ad  libitum. The 
studies were performed under isoflurane anesthesia. The 
mice were fasted for 4 h before the 18F-FDG injection to 
standardize plasma glucose level. Since fasting had not 
shown any detectable effect on choline uptake in previ-
ous studies [29] or in our pre-study (see Additional file 1), 
the mice were not fasted before the 18F-FMCH injection.
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Radiotracers
The 18F-FMCH batches were purchased from MAP 
Medical Technologies Oy (Helsinki, Finland). The radio-
chemical purity exceeded 95 % in every batch. 18F-FDG 
was synthesized in the radiopharmaceutical laboratory 
of Turku PET Centre. 18F-FMCH in  vivo stability was 
assessed by radio-HPLC (see Additional file 1).
In vivo PET/CT imaging
In order to study the distribution kinetics of 18F-FMCH, 
three IGF-II/LDLR−/−ApoB100/100 mice were imaged 
with Inveon Multimodality small animal PET/CT scan-
ner (Siemens Medical Solutions, Knoxville, TN, USA). 
The mice were injected with approximately 6  MBq of 
18F-FMCH via tail vein and a dynamic 30-minute PET 
was started at the same time. After PET imaging, 100–
150 µl of intravenous contrast agent (eXia 160XL, Binitio 
Biomedical, Ottawa, Ontario, Canada) was injected and 
a high-resolution CT imaging was performed. The CT 
acquisition consisted of 270 projections with the expo-
sure time of 1250 ms for a full 360° rotation. X-ray volt-
age was 80 kVp and anode current 500 µA.
PET data acquired in a list mode were iteratively recon-
structed with a 2-dimensional ordered-subsets expecta-
tion maximization algorithm into 30 × 10 s and 15 × 60 s 
frames. A reconstructed image had 128  ×  128  ×  159 
matrix size with a pixel size of 0.776 × 0.776 × 0.796 mm. 
CT images were reconstructed with a filtered back-pro-
jection algorithm (pixel size 0.094 × 0.094 × 0.094 mm). 
In vivo PET and CT images were co-registered and 
dynamic PET data was analyzed with Carimas 2.8 soft-
ware (Turku PET Centre, Turku, Finland). Regions of 
interest (ROI) were defined in selected tissues based on 
the high-resolution CT in order to obtain time-activity 
curves. The ROI for blood pool was located in vena cava.
Ex vivo PET imaging
For a subset of mice studied with 18F-FMCH (3 
LDLR−/−ApoB100/100 and 3 C57BL/6N mice), an ex  vivo 
PET was performed for the aorta and heart. The mice 
were killed at 20 min post-injection, the aortas and hearts 
were excised, measured for radioactivity and positioned 
into a tube filled with ultrasonography gel. The tube was 
placed in the PET camera (Inveon Multimodality small 
animal PET/CT scanner, Siemens Medical Solutions, 
Knoxville, TN, USA) and static 40-minute min PET was 
performed. PET data were reconstructed with a 3-dimen-
sional ordered-subsets expectation maximization algo-
rithm. A reconstructed image had 128  ×  128  ×  159 
matrix size with a pixel size of 0.776 × 0.776 × 0.796 mm.
Blood sampling and ex vivo tracer distribution 
measurement
The mice were i.v. injected with 10–11 MBq of 18F-FMCH 
or 18F-FDG and killed with cardiac puncture and cervical 
dislocation under deep anesthesia at 20 or 90  min post-
injection, respectively. The time points were chosen based 
on tracer-specific kinetics [23, 30]. Approximately 50  µl 
of blood was measured for radioactivity. The rest of the 
blood sample was centrifuged and the separated plasma 
was stored at −70  °C for further analyses. To assess the 
distribution of the radiotracers, the aortas and selected 
other tissues were excised, weighed and measured using 
a gamma counter (1480 Wizard 3″; Perkin Elmer/Wallac, 
Turku, Finland or Triathler 3″, Hidex, Turku, Finland). 
Radioactivity concentration was decay-corrected to the 
injection time and expressed as percentage of injected 
radioactivity dose per gram of tissue (% IA/g).
Autoradiography of aortic sections
The distribution of 18F-FMCH and 18F-FDG in the aortas 
of mice was further studied by autoradiography. The aor-
tas were frozen in ice-cold isopentane, cut into sequential 
20- and 8-µm sections and apposed to an imaging plate 
for digital autoradiography. After an overnight exposure, 
the plates were scanned with Fuji Analyzer BAS-5000 
(Fuji, Tokyo, Japan; internal resolution 25  μm) and the 
sections were stored at −70 °C.
Table 1 Characteristics of the study animals
LDLR−/−ApoB100/100 non-diabetic atherosclerotic mice, IGF-II/LDLR−/−ApoB100/100 diabetic atherosclerotic mice; C57BL/6N healthy control mice; PET/CT positron emission 
tomography/computed tomography; ARG autoradiography; NA not applicable. The data are expressed as mean ± SD











18F‑FMCH LDLR−/−ApoB100/100 11 (7/4) 33.2 ± 6.0 6.5 ± 0.1 4.4 ± 0.0 9.4 ± 0.9 8
IGF‑II/LDLR−/−ApoB100/100 11 (6/5) 32.4 ± 6.8 6.4 ± 0.3 3.9 ± 0.5 10.3 ± 0.6 11
C57BL/6N 13 (9/4) 38.2 ± 7.9 8.0 ± 2.6 NA 11.3 ± 2.2 6
PET/CT IGFII/LDLR−/−ApoB100/100 3 (0/3) 25.0  ± 3.1 4.6 ± 0.0 2.8 ± 0.0 5.7 ± 0.5 3
18F‑FDG LDLR−/−ApoB100/100 12 (8/4) 35.8 ± 8.8 6.6 ± 0.3 4.4 ± 0.2 11.2 ± 1.8 12
IGF‑II/LDLR−/−ApoB100/100 11 (6/5) 34.7 ± 7.6 6.5 ± 0.4 4.2 ± 0.3 10.8 ± 1.4 11
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The autoradiography analysis was performed with 
TINA 2.1 software (Raytest Isotopemessgeräte, GmbH, 
Straubenhardt, Germany). In the autoradiographs of the 
20-µm sections, ROIs were defined in plaques (exclud-
ing calcifications), adjacent histologically normal vessel 
wall and vessel-surrounding adventitia, based on hema-
toxylin-eosin staining (H&E). Background counts were 
subtracted and results expressed as photo-stimulated 
luminescence (PSL)/mm2. The values were normalized 
for injected radioactivity, mouse weight and radioactivity 
decay during exposure. On average, 50 ROIs for plaque, 
25 for wall and 27 for adventitia per animal were ana-
lyzed. For atherosclerotic mice, plaque-to-wall uptake 
ratio was calculated.
Histology and immunohistochemistry
The 20-µm aortic sections were stained with H&E for 
histological evaluation. In order to assess the plaque 
inflammation, the 8-µm sections were immunostained 
for macrophages with anti-Mac-3 antibody (clone M3/84, 
1:5000, BD Pharmingen, Franklin Lakes, NJ, USA) as 
described before [31]. Additional 8-µm sections were 
stained with anti-Ki-67 antibody (clone TEC-3, M7249, 
1:1000, Dako, Glostrup, Denmark) to detect cell pro-
liferation. Aortic roots (n  =  8–9/group) were forma-
lin-fixed, paraffin-embedded, and cut into serial 5-µm 
sections for the histological comparison of the charac-
teristics of atherosclerosis in LDLR−/−ApoB100/100 and 
IGF-II/LDLR−/−ApoB100/100 mice. The sections were 
stained with Movat’s pentachrome to assess the plaque 
burden, expressed as intima-to-media ratio (IMR). Mac-
rophages were stained with anti-Mac-3 antibody. Addi-
tionally, sections were stained with anti-inducible nitric 
oxide synthase (iNOS) or anti-mannose receptor C-type 
1 (MRC-1) antibodies to detect M1 (pro-inflammatory) 
and M2 (anti-inflammatory) polarized macrophages, 
respectively. Immunohistochemical staining for scaven-
ger receptor CD36, involved in the atherogenesis, was 
also performed. The staining protocols are described in 
Additional file 1 and the analyses in [32].
Comparison of 18F-FMCH uptake and macrophages 
in plaques
To compare 18F-FMCH uptake and inflammation 
(amount of macrophages), a subset of diabetic mice 
(n  =  8) was studied. In autoradiographs, ROIs were 
defined in plaque areas showing no or only few mac-
rophages and areas with macrophage infiltration. Based 
on the areal percentage of Mac-3-positive staining as 
quantified with ImageJ software (Fiji, National Insti-
tutes of Health, Bethesda, MD, USA), the plaque areas 
were classified as representing low, intermediate or high 
macrophage density. 18F-FMCH uptake in the areas was 
expressed as PSL/mm2 as described above.
Correlation of 18F-FMCH plaque uptake and plasma 
biomarkers
Plasma samples from eleven LDLR−/−ApoB100/100, eleven 
IGF-II/LDLR−/−ApoB100/100 and nine C57BL/6N mice 
were analyzed for lipids and lipid-associated proteins (total 
cholesterol, phospholipids, triglycerides, phospholipid 
transfer protein [PLTP] and paraoxonase-1 [PON-1]), met-
abolic markers (glucagon, glucose, C-peptide, insulin and 
leptin), and inflammatory mediators (interferon-γ [IFN-γ], 
interleukin-6 [IL-6], monocyte chemoattractant protein-1 
[MCP-1] and cytokine regulated on activation, normal T 
cell expressed and secreted [RANTES]) (see Additional 
file  1). The markers in plasma were plotted against the 
mean 18F-FMCH uptake in plaques measured by autoradi-
ography (PSL/mm2) in each mouse.
Statistical analyses
Results are expressed as mean  ±  SEM unless otherwise 
specified. Statistical analyses were conducted with IBM 
SPSS Statistics 21 (IBM Corp., Armonk, NY, USA). The 
comparisons between two groups were made using inde-
pendent samples t test, and the comparisons between multi-
ple groups using one-way ANOVA with Tukey or Tamhane 
correction. Paired t-test was applied when comparing 
uptake between different tissues in the same animals. The 
correlations were assessed with Pearson’s coefficient (r). The 
p values <0.05 were considered statistically significant.
Results
Total cholesterol levels were similar in non-dia-
betic (LDLR−/−ApoB100/100) and diabetic (IGF-II/
LDLR−/−ApoB100/100) mice (31 ± 4.3 and 36 ± 12 mmol/l, 
respectively), as were also the fasting glucose levels 
(7.8  ±  1.0 and 9.1  ±  3.1  mmol/l, respectively). There 
was a tendency towards higher blood levels of insulin, 
C-peptide and IL-6 in diabetic mice (Additional file  1: 
Table S3). The total cholesterol was significantly lower 
in C57BL/6N control than in the hypercholesterolemic 
mice (1.8 ± 0.3, p < 0.001).
The aortas of both non-diabetic and diabetic hyper-
cholesterolemic mice showed extensive atherosclerosis, 
mainly fibroatheroma-type lesions with large, confluent 
areas of Mac-3-positive macrophages, whereas no ath-
erosclerosis was observed in control mice (Fig.  1). All 
plaques showed positivity for iNOS and MRC-1, indi-
cating M1 and M2 polarized macrophages, respectively. 
The scavenger receptor CD36 co-localized with the mac-
rophage-positive areas of plaques, while only occasional 
Ki-67 positive cells were observed. Occasional plaque 
Page 5 of 13Hellberg et al. Cardiovasc Diabetol  (2016) 15:26 
calcifications were seen in 60 % of non-diabetic and 73 % 
of diabetic mice. The plaques of non-diabetic and dia-
betic mice showed no difference in any of the measured 
histological characteristics (Table 2).
In vivo PET/CT imaging
Figure  2a, b shows a representative whole-body 
18F-FMCH PET/CT image and average time-activity 
curves of selected tissues in three atherosclerotic mice. 
18F-FMCH radioactivity was cleared from the blood rap-
idly after injection and the uptake in tissues reached a 
plateau between 15 and 20 min post-injection. Therefore, 
a 20 min time point was chosen for ex vivo studies. The 
highest radioactivity concentrations were observed in kid-
neys and liver.
Ex vivo 18F-FMCH PET imaging revealed focal areas 
of high tracer uptake in the aortic arch of atherosclerotic 
mice, as compared with the lower and homogeneous 
uptake in the aortas of healthy control mice. PET images 
of the aorta and the heart are shown in Fig. 2c.
Uptake of 18F-FMCH in diabetic atherosclerosis
The uptakes of 18F-FMCH in aorta and other tissues are 
shown in Table  3. Aortic 18F-FMCH uptake was higher 
in diabetic than non-diabetic atherosclerotic mice or 
healthy controls (p = 0.025 and p < 0.001, respectively). 
The remaining blood radioactivity was lower in diabetic 
than non-diabetic mice (p = 0.0050), and thus, the aorta-
to-blood ratio was higher (p =  0.017). The radioactivity 
concentrations in urine also tended to be lower in dia-
betic than non-diabetic mice (p = 0.058).
Autoradiography showed strong and clearly delin-
eated accumulation of 18F-FMCH in atherosclerotic 
plaques in both diabetic and non-diabetic mice (Fig. 3; 
Table  4). 18F-FMCH uptake was significantly higher in 
plaques than in normal vessel wall or adventitia. In the 
normal vessel wall, uptake of 18F-FMCH was similar in 
non-diabetic and diabetic atherosclerotic mice and in 
controls. 18F-FMCH uptake in plaques was higher in 
diabetic mice, but the plaque-to-wall ratios were simi-
lar in non-diabetic and diabetic mice (2.5  ±  0.10 and 
2.6 ± 0.085, p = 0.19).
Fig. 1 Histology of atherosclerotic plaques in non‑diabetic 
LDLR−/−ApoB100/100 and diabetic IGF‑II/LDLR−/−ApoB100/100 mice. 
The sections are from aortic roots (scale bar 100 µm) except for Ki‑67, 
which is from aortic arch (scale bar for inset 20 µm). Movat: histology 
(black = nuclei; yellow = collagen, reticular fibers; blue = ground 
substance, mucin; red = muscle), Mac‑3: macrophages, iNOS: M1 
polarized macrophages, MRC‑1: M2 polarized macrophages, CD36: 
macrophage scavenger receptor, Ki‑67: proliferative cells
Table 2 Quantitative results of  histology in  non-diabetic 
(LDLR−/−ApoB100/100) and diabetic (IGF-II/LDLR−/−ApoB100/100) 
atherosclerotic mice
In addition to plaque size (intima-to-media ratio), areal percentages of 
macrophages (Mac-3), M1 polarized macrophages (iNOS), M2 polarized 
macrophages (MRC-1) and scavenger receptor (CD36) in atherosclerotic lesions 
in the aortic root are shown. The data are expressed as mean ± SEM. No 







2.7 ± 0.88 1.8 ± 0.51
Mac‑3 positive area (%) 15 ± 2.3 17 ± 0.98
iNOS positive area (%) 14 ± 1.3 14 ± 1.7
MRC‑1 positive area (%) 30 ± 1.3 32 ± 1.2
CD36 positive area (%) 24 ± 1.6 28 ± 0.66
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Comparison of 18F-FMCH plaque uptake and macrophages 
in immunohistochemistry
The uptakes of 18F-FMCH were compared in plaque areas 
with low, intermediate or high areal percentage of Mac-3 
staining. The obtained average areal percentages were 12, 
38 and 52 %, respectively. The uptake of 18F-FMCH was 
significantly higher in areas with high than low areal per-
centage of Mac-3-staining (110 ±  5.3 vs. 81 ±  4.5 PSL/
mm2, p = 0.0027, Fig. 4).
Correlation of 18F-FMCH plaque uptake and plasma 
biomarkers
The average 18F-FMCH uptake in plaques (pooled data 
from non-diabetic and diabetic mice) showed posi-
tive correlation with plasma levels of total cholesterol 
(r = 0.77, p < 0.001), PLTP (r = 0.56, p = 0.013), C-pep-
tide (r = 0.69, p = 0.0010), insulin (r = 0.73, p < 0.001) 
and leptin (r = 0.68, p = 0.0013). A trend towards posi-
tive correlation was observed with plasma PON-1 
Fig. 2 In vivo and ex vivo PET Imaging. a Whole‑body 18F‑FMCH PET/CT image of an IGF‑II/LDLR−/−ApoB100/100 mouse. b Mean time‑activity curves 
of radioactivity in selected tissues from three mice. c Representative 18F‑FMCH PET image of the aorta (left) and heart (right) of atherosclerotic 
LDLR−/−ApoB100/100 and healthy C57BL/6N mice. High focal uptake can be seen in the aortic arch of the LDLR−/−ApoB100/100 mouse (arrow)
Table 3 Ex vivo distribution of 18F-FMCH
The distribution of 18 F-FMCH is measured at 20 min post-injection in non-diabetic (LDLR−/−ApoB100/100) and diabetic (IGF-II/LDLR−/−ApoB100/100) atherosclerotic mice 
and in healthy (C57BL/6N) controls. The results are expressed as percentage of injected radioactivity dose per gram of tissue (mean ± SEM)
a a significant difference as compared with C57BL/6N mice
b a significant difference as compared with LDLR−/−ApoB100/100 mice
LDLR−/−ApoB100/100 IGF-II/LDLR−/−ApoB100/100 C57BL/6N
Aorta 1.5 ± 0.11 2.0 ± 0.17a, b 1.2 ± 0.094
Blood 0.98 ± 0.076 0.58 ± 0.066b 0.84 ± 0.090
Intestine 8.1 ± 0.75 11 ± 2.0 8.7 ± 2.9
Kidney 49 ± 2.8 41 ± 5.1 37 ± 3.2
Liver 19 ± 2.8 13 ± 2.0 18 ± 2.9
Lungs 11 ± 0.48 13 ± 1.0a 9.2 ± 0.77
Muscle 0.91 ± 0.086 1.2 ± 0.10 0.86 ± 0.12
Myocardium 6.8 ± 0.44 8.4 ± 0.80 6.3 ± 0.64
Pancreas 7.7 ± 0.78 8.1 ± 0.86 6.0 ± 0.42
Spleen 6.6 ± 0.30 6.7 ± 0.77 5.0 ± 0.61
Urine 20 ± 5.4 6.3 ± 2.1 15 ± 4.0
White adipose tissue 0.50 ± 0.12 0.51 ± 0.12 0.29 ± 0.040
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activity (r  =  0.43, p  =  0.066), whereas no correlation 
was observed with plasma glucose (r = −0.25, p = 0.32). 
There was a trend towards positive correlation between 
the uptake of 18F-FMCH in plaques and the blood lev-
els of IL-6 (r = 0.46, p = 0.053) and RANTES (r = 0.40, 
p =  0.10). No correlation was observed to other meas-
ured markers. The correlation plots are shown in Fig.  5 
and Supplemental Fig. 4 in Additional file 1.
Comparison of 18F-FMCH and 18F-FDG uptakes in the 
atherosclerotic aorta
Representative 18F-FDG and 18F-FMCH autoradiographs 
of the mouse aortic arch are shown in Fig.  3. Average 
plaque-to-wall ratios were similar between 18F-FMCH 
and 18F-FDG in non-diabetic mice, but significantly higher 
with 18F-FMCH than 18F-FDG in diabetic mice (Fig.  6). 
Gamma counting showed that the absolute uptake of 
18F-FMCH in the whole aorta was lower than that of 18F-
FDG in both diabetic (2.0 ±  0.17 vs. 4.7 ±  0.41  % IA/g, 
p < 0.001) and non-diabetic mice (1.5 ± 0.11 vs. 5.0 ± 0.40, 
p < 0.001). However, the aorta-to-blood ratios of the trac-
ers were similar in diabetic mice (3.9 ± 0.65 vs. 3.6 ± 0.49, 
p  =  0.70), whereas in non-diabetic mice, the ratio was 
lower with 18F-FMCH than with 18F-FDG (1.6 ± 0.14 vs. 
4.9 ± 0.68, p < 0.001). The uptake of 18F-FMCH in myo-
cardium was, however, lower than that of 18F-FDG in 
both diabetic (8.4 ± 0.80 vs. 65 ± 8.0 % IA/g, p < 0.001) 
and non-diabetic (6.8 ± 0.44 vs. 49 ± 4.7, p < 0.001) mice, 
resulting in a higher aorta-to-myocardium ratio (Fig. 6).
Discussion
The uptake of the PET tracer 18F-FMCH is increased 
in the atherosclerotic aorta of mice with T2DM. The 
uptake in atherosclerotic plaques was associated with 
the amount of Mac-3 positive macrophages in plaques, 
as well as the plasma levels of total cholesterol, certain 
metabolic markers and cytokines. In comparison with 
18F-FDG, 18F-FMCH provided similar or higher target-
to-background ratios between atherosclerotic plaques 
and the normal vessel wall, as well as aorta and blood or 
myocardium in diabetic mice. These results indicate that 
T2DM is associated with increased uptake of choline in 
atherosclerosis and that 18F-FMCH may be useful for the 
evaluation of vascular inflammation in diabetes.
Studies using 18F-FDG PET have revealed subclini-
cal vascular inflammation in patients with abnormal 
glucose metabolism [6–8]. More recent studies have 
indicated contribution of pericardial and visceral fat 
to vascular inflammation [9, 33]. Molecular imaging 
of vascular inflammation is a potential tool to study 
mechanisms of atherosclerosis, effects of therapies and 
eventually risk of CVD in high-risk individuals, such as 
those with diabetes [4].
The LDLR−/−ApoB100/100 mouse model is a well 
characterized and widely utilized model of hypercho-
lesterolemia and atherosclerosis. Abnormalities in 
apolipoprotein E (ApoE) rarely contribute to human 
hypercholesterolemia, and therefore, the LDLR−/− mouse 
model better mimics the human disease. The addition of 
the gene modification leading to the expression of only 
apolipoprotein B100 on the LDLR−/− background further 
raises the cholesterol level and amplifies the progression 
of atherosclerosis [28]. Despite the only mildly elevated 
fasting glucose levels, the IGF-II/LDLR−/−ApoB100/100 
mice overexpressing IGF-II in pancreatic beta cells 
represent the insulin resistance and impaired glu-
cose tolerance that is consistent with the T2DM phe-
notype. Although their lipid profile is similar to that of 
the LDLR−/−ApoB100/100, the diabetic mice represent 
accelerated development of macrovascular complica-
tions, including more calcified, less organized and more 
complex lesions with higher IL-6 expression [27, 34]. 
Our findings of elevated plasma insulin, C-peptide and 
IL-6 levels are in line with the T2DM phenotype. Taken 
together, these data suggest a more pro-inflammatory 
milieu in the diabetic IGF-II/LDLR−/−ApoB100/100 mice 
as compared with the non-diabetic LDLR−/−ApoB100/100 
mice.
The 18F-FMCH uptake was increased in the athero-
sclerotic aorta of diabetic mice as compared with non-
diabetic mice. In addition, the correlations between 
the 18F-FMCH plaque uptake and the plasma C-pep-
tide, insulin and leptin levels support the association 
of the uptake to diabetic phenotype. In both diabetic 
and non-diabetic mice, the plaques represented simi-
lar amounts of M1 and M2 polarized macrophages and 
also scavenger receptor CD36. Therefore, the higher 
18F-FMCH uptake in the inflamed plaques may reflect 
increased choline transport [23] and metabolism in the 
macrophages. Interestingly, 18F-FMCH seems to have 
an enhanced cellular intake in diabetic mice, since the 
tracer tends to be more cleared from the blood and 
less excreted in the urine at the 20-minute time point 
as compared with non-diabetic mice. The absolute 
uptake of 18F-FMCH was higher in the aortas of diabetic 
mice as compared with non-diabetic mice, as was also 
the aorta-to-blood uptake ratio due to lower remain-
ing tracer in circulation. Because blood will always be 
included in the ROI due to the limited resolution of PET 
images, high aorta-to-blood ratio is a good property for 
the in  vivo imaging of tracer uptake in atherosclerotic 
plaques.
In the current study, the plaque-to-wall uptake ratio of 
18F-FMCH (on average 2.6) was within the same range 
as that of 11C-choline (2.3) or 18F-fluorocholine (3.5) in 
previous studies in mice [22, 23]. In line with previous 
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Fig. 3 Histology and 18F‑FMCH and 18F‑FDG autoradiography of atherosclerotic aortas in diabetic IGF‑II/LDLR−/−ApoB100/100 mice. Scale bar 500 µm. 
Both tracers show focal uptake in the atherosclerotic plaques (P) in the aortic arch and its branches. W normal vessel wall, A adventitia, C calcifica‑
tion, L lumen
Table 4 Aortic uptake of 18F-FMCH and 18F-FDG in ex vivo autoradiography
Uptake of the tracers in different parts of vascular tissue are measured in non-diabetic (LDLR−/− ApoB100/100) and diabetic (IGF-II/LDLR−/−ApoB100/100) atherosclerotic 
mice and in healthy (C57BL/6N) controls. The results are expressed as count densities (photo-stimulated luminescence per mm2, mean ± SEM). 
NA not applicable
a a significant difference as compared with LDLR−/−ApoB100/100 mice
18F-FMCH 18F-FDG
LDLR−/−ApoB100/100 IGF-II/LDLR−/−ApoB100/100 C57BL/6N LDLR−/−ApoB100/100 IGF-II/LDLR−/−ApoB100/100
Adventitia 140 ± 9.1 160 ± 12 100 ± 8.4a 210 ± 39 130 ± 12
Wall 76 ± 5.8 89 ± 6.8 69 ± 7.5 160 ± 18 140 ± 12
Plaque 190 ± 11 240 ± 20a NA 320 ± 30 290 ± 20
Plaque‑to‑wall ratio 2.5 ± 0.10 2.6 ± 0.085 NA 2.1 ±0.16 2.1 ± 0.16
Plaque vs. wall p value <0.001 <0.001 NA 0.0023 <0.001
Plaque vs. adventitia p value 0.018 0.022 NA 0.061 <0.001
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observations, we discovered that 18F-FMCH accumu-
lated in the most inflamed plaques, as shown by high 
macrophage density. The plaque uptake of 18F-FMCH 
also showed correlation with different metabolic and 
inflammatory markers. Elevated levels of total choles-
terol, PLTP, RANTES, IL-6, insulin and leptin, which 
showed correlation with 18F-FMCH uptake, have been 
linked with increased atherosclerosis [35–42] thus lend-
ing support to the association between 18F-FMCH uptake 
and the risk of atherosclerosis. Recent reports, however, 
suggest that PLTP activity is inversely correlated with 
carotid artery disease and linked with PON-1 [43], and 
that PON-1 is regarded as an atheroprotective enzyme 
[44, 45].
In previous studies, arterial uptake of 18F-FDG or 
11C-choline did not typically co-localize with calcifica-
tions seen on CT supporting the concept that inflam-
mation and calcification occur at different stages of 
atherosclerosis [4, 25]. Our findings with 18F-FMCH sug-
gest the same pattern since vascular tracer uptake was 
lower in 9-month-old mice (% IA/g 1.7, plaque-to-wall 
ratio 2.2, see Additional file 1) than in 6-month-old mice 
(% IA/g 2.0, plaque-to-wall ratio 2.6), despite more exten-
sive vascular calcification (calcifications in all animals at 
the age of 9 months vs. in 73 % of animals at the age of 
6 months), but less macrophages.
Although 18F-FDG is the most commonly used tracer 
for atherosclerotic plaque imaging, the high physiological 
tracer uptake in the myocardium has limited its applica-
tion for imaging coronary artery inflammation, although 
it is possible to reduce the uptake by means of metabolic 
interventions [4]. In this study, the myocardial uptake 
was lower for 18F-FMCH than for 18F-FDG, and, moreo-
ver, the myocardial uptake of 11C-choline has been neg-
ligible in patients [25], thus promoting the feasibility of 
18F-FMCH in coronary artery imaging. As compared 
with 18F-FDG, 18F-FMCH showed superior plaque-to-
wall ratio, equal aorta-to-blood ratio and higher aorta-
to-myocardium ratio in the diabetic mice, suggesting 
potential for monitoring atherosclerosis progression in 
diabetes.
There are some limitations in our study. The rea-
sons for insulin resistance in our mouse model are not 
fully understood, the model does not represent the full 
Fig. 4 18F‑FMCH uptake and the density of macrophages in atherosclerotic plaques in diabetic IGF‑II/LDLR−/−ApoB100/100 mice. a Macrophage 
immunostaining (Mac‑3, brown) of aortic plaque. The dotted line separates areas of visually high and low macrophage density. Scale bar 100 µm. b 
Binary image from ImageJ software shows Mac‑3‑positive staining as black, and the areal percentage of positive staining is measured. c Autoradio‑
graph of the plaque shows high radioactivity co‑localizing with the Mac‑3‑positive staining. d Quantitative uptake of 18F‑FMCH in plaque areas with 
low, intermediate or high areal percentage of Mac‑3‑positive staining
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phenotypic spectrum of T2DM in patients, and our 
findings need to be verified in clinical studies [46]. The 
feasibility of 18F-FMCH for detecting atherosclerotic 
plaque inflammation by in vivo PET imaging remains to 
be investigated because, in our study, only young IGF-
II/LDLR−/−ApoB100/100 mice were imaged with PET/
CT and it was not possible to visualize the small plaques 
existing at the young age. Taken together, our findings 
support the concept of utilizing choline-based radiophar-
maceuticals in the imaging of inflammation in diabetic 
atherosclerosis, but further in  vivo imaging studies in 
patients are needed to proof this.
Fig. 5 Correlation of 18F‑FMCH uptake and plasma levels of lipids, metabolic markers and cytokines. Pooled data from non‑diabetic 
LDLR−/−ApoB100/100 and diabetic IGF‑II/LDLR−/−ApoB100/100 mice. PLTP phospholipid transfer protein; PON-1 paraoxonase‑1; IL-6 interleukin‑6; 
RANTES cytokine regulated on activation, normal T cell expressed and secreted
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Conclusions
The uptake of the radiolabeled choline derivative 
18F-FMCH was increased by type 2 diabetes in the aor-
tas of atherosclerotic mice and reflected inflammation in 
atherosclerotic plaques. Comparison with 18F-FDG indi-
cates that 18F-FMCH is a potential tracer for monitoring 
the atherosclerotic vascular inflammation in diabetes.
Additional file
Additional file 1. Supplemental data.
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